In a retrospective study using C-peptide-positive patients with T1D, the combination of GLP-1 receptor agonists and insulin treatment could effectively reduce HbA1c from 10.74 ± 0.96% to 7.4 ± 0.58% (P < 0.01), and body weight from 71 ± 2.0 to 69 ± 2 kg (P = 0.06), which supported the efficacy for this combination therapy (60). The gene discussed is INS; the disease is type 1 diabetes mellitus.